Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=program_officials" }, "data": [ { "type": "Grant", "id": "15319", "attributes": { "award_id": "1R44CA295355-01", "title": "PyroTIMER Technology: Enabling T-Cell Persistence in Immunosuppressive Tumor Microenvironments", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31912, "first_name": "SWAMY KRISHNA", "last_name": "Tripurani", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-23", "end_date": "2026-08-31", "award_amount": 748337, "principal_investigator": { "id": 31913, "first_name": "ARCHIS", "last_name": "BAGATI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2532, "ror": "", "name": "PYROJAS INC", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The challenge of effectively treating cancer is further complicated by the limitations of current CAR-T cell therapies, especially when confronted with the immunosuppressive tumor microenvironment (TIME). Central to this issue is the transforming growth factor-beta (TGF-β), which induces T cell exhaustion and curtails their antitumor potency. Current methodologies to inhibit the TGF-β pathway have yielded suboptimal results due to transient effects. This project introduces PyroTIMER CAR-T cells, an innovative approach that promises durable inhibition of all TGF-β isoforms within the TIME. This robust strategy not only targets TGF-β with unprecedented potency but also incorporates multiple technical advancements, enhancing T cell cytotoxicity and leveraging patient-derived xenograft (PDX) models for a more accurate representation of the tumor milieu. The overarching research plan is to thoroughly assess PyroTIMER CAR-T cells in both immunocompetent syngeneic models and PDX models. Employing multi-parametric flow cytometry, we aim to delve into the immune dynamics within tumors, elucidating how PyroTIMER CAR-T cells interact with and potentially remodel the TIME. Our objectives are four-fold: 1. Deciphering the influence of TGF-β on PyroTIMER CAR-T cells. 2. Profiling cytokine production to gauge risks, particularly concerning cytokine release syndrome (CRS). 3. Investigating potential exhaustion scenarios in PyroTIMER CAR-T cells. 4. In-depth in vivo evaluations of the safety and efficacy of PyroTIMER CAR-T cells. Our long-term trajectory is underpinned by a commitment to patient safety and therapeutic efficacy. By forging collaborations with pharmaceutical entities, refining manufacturing strategies for scalability, and seeking FDA endorsement, we aspire to position PyroTIMER CAR-T cells at the forefront of personalized cancer therapies. This initiative represents a harmonious blend of advanced scientific inquiry, patient well-being, and strategic commercial planning. Through this endeavor, we aim to redefine CAR-T cell therapy, presenting a novel, potent, and safer treatment paradigm for cancer patients.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15321", "attributes": { "award_id": "1R44CA287634-01A1", "title": "CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31914, "first_name": "SAROJ GOPAL", "last_name": "Regmi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-20", "end_date": "2026-08-31", "award_amount": 994859, "principal_investigator": { "id": 31915, "first_name": "ARTHUR P", "last_name": "BERTOLINO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1011, "ror": "", "name": "CYTOAGENTS, INC.", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "CytoAgents is developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy has emerged as a very promising treatment option for patients with relapsed or refractory (R/R) hematologic malignancies. However, CAR T-cell therapy can also result in a high incidence of severe and potentially life-threatening immune-mediated toxicity, including CRS and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS is a systemic inflammatory response that has been reported as one of the most frequent and dangerous adverse events following CD19-directed CAR T-cell therapy. CRS is thought to be mediated by an initial release of proinflammatory cytokines, which activate bystander immune cells and endothelial cells, which in turn activate more immune cells, culminating in a cytokine storm. Because CytoAgents’ novel approach is focused on reducing the transcription of multiple proinflammatory cytokines, its compound is expected to mitigate, and in some cases even prevent, CRS. CTO1681 is an orally available, stable compound identical to beraprost sodium-314d (BPS-314d), the stereoisomer of the racemate beraprost sodium (BPS) that accounts for nearly all of BPS’s pharmacological activity. Because BPS can modulate the release of cytokines from human peripheral blood mononuclear cells, CytoAgents has investigated the use of BPS and its active isomer CTO1681 as a treatment for moderate virus-induced CRS, specifically influenza and COVID-19. All of the results to date indicate that CTO1681 has strong potential to reduce the CRS response, leading to better patient outcomes regardless of CRS etiology. Overall, BPS, BPS-314d, and CTO1681 formulations have been found to be well tolerated and to not completely suppress cytokine levels in healthy volunteers with normal serum levels. CytoAgents is currently expanding clinical investigation of CTO1681 to the treatment of CAR T-cell therapy-induced CRS. CytoAgents’ Phase 1b trial of CTO1681, a multicenter, open-label, dose-escalating safety and pharmacokinetic (PK) MAD study in patients with diffuse large B cell lymphoma (DLBCL) receiving CD19-directed CAR T-cell therapy, is scheduled to begin in the coming months. This Direct to Phase II project will support expansion to a Phase 2a cohort once the recommended Phase 2 dose (RP2D) has been determined. The company will undertake three specific aims: 1) determining preliminary efficacy of CTO1681 in preventing or reducing CRS or ICANS vs. historical or placebo treatment, 2) determining the expanded safety profile of CTO1681 in patients with DLCBL receiving CAR T-cell therapy, and 3) investigating the potential impact of CTO1681 on antitumor activity of CAR T-cell therapy compared to historical data and placebo. This project will help support clinical assessment of CTO1681 in CAR T-cell therapy recipients, advancing a novel treatment with the potential to reduce hospitalization, intensity of supportive care, and mortality and to improve patients’ quality of life. Moreover, this therapeutic may allow more patients with R/R hematologic malignancies to have access to potentially life-saving CAR T-cell treatment.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15322", "attributes": { "award_id": "1R35GM155224-01", "title": "Observational causal inference with infectious disease outcomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 31916, "first_name": "Guoqin", "last_name": "Yu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-15", "end_date": "2029-07-31", "award_amount": 382852, "principal_investigator": { "id": 31917, "first_name": "Alyssa", "last_name": "Bilinski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 222, "ror": "https://ror.org/05gq02987", "name": "Brown University", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "Infectious disease is a leading cause of global morbidity and mortality. Transmission dynamic models have played a critical role in guiding interventions related to many infectious pathogens, including HIV, influenza, SARS-CoV-1, ebolaviruses, SARS-CoV-2, and mpox. Models project how potential interventions (e.g., non- pharmaceutical measures, therapeutics, and vaccines) may affect disease future transmission. However, they often rely on small scale studies to project effects, and there have been growing concerns that models may produce inaccurate, overly optimistic estimates of population-level intervention effectiveness. Observational causal inference models, which measure intervention effectiveness in real-world settings, could help address this limitation, but applying these to infectious disease is not straightforward. Observational approaches, such as difference-in-differences and synthetic control methods, estimate the impact of an intervention based on empirical counterfactuals: comparing outcomes of interest between treated units or places and similar untreated units. While well-understood with linear outcomes, they can produce biased and misleading results in the context of nonlinear transmission dynamics. Even where observational models perform well, it further remains challenging to transport estimates to new settings to project the impact of future interventions. To address these issues, this project will develop comprehensive theoretical architecture for synthesizing transmission dynamic models with observational causal inference models – employing empirical counterfactuals while accounting for complex biological and population dynamics. In the retrospective workstream, I will propose robust specifications for observational causal inference models that can estimate unbiased treatment effects in policy evaluations using infectious disease outcomes. I will also develop model selection and decision-analytic methods to address potentially significant parameter uncertainty. In the prospective workstream, I will develop approaches to generalize estimates from observational causal inference models to new settings using transmission dynamic models and update projected effects in real-time based on local surveillance indicators. I will illustrate the implications of our methods by re-analyzing prior studies on COVID-19 as well as applying them to answer new questions about respiratory illness control, in collaboration with partners in state and local public health institutions. Across both workstreams, I will develop and disseminate open-source public tools and software to facilitate adoption of these methods. Overall, this work will produce a suite of methodological innovations to improve understanding of the impact of past policies and the accuracy of future projections, while also supporting their implementation in public health institutions to guide planning and priority setting.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15449", "attributes": { "award_id": "5R01GM152743-02", "title": "Collaborative Research: DMS/NIGMS 1: Identifiability investigation of Multi-scale Models of Infectious Diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 31916, "first_name": "Guoqin", "last_name": "Yu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-27", "end_date": "2026-07-31", "award_amount": 278462, "principal_investigator": { "id": 28183, "first_name": "Stanca M.", "last_name": "Ciupe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 839, "ror": "", "name": "VIRGINIA POLYTECHNIC INST AND ST UNIV", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "The emergence and re-emergence of pathogens and their impact on society has reinforced the need for integration and synergy across scientific fields and biological scales in order to advance understanding, predicting, and responding to pathogen spread. Multi-scale mathematical models that consider the timing and length of individual infections when modeling transmission into the population can aid recommendations for optimal interventions. One shortcoming when evaluating data using multi-scale models comes from data scarcity in the expansion stages of the infection and transmission, the differences in data magnitude and frequency at each scale, together with the complexity of the models considered. To determine the source of combined biases in parameter estimation, we will use a combined empirical-theoretical approach for investigating structural and practical parameter identifiability of multi-scale models of infectious diseases that may inform optimal experimental design. The proposed research will facilitate a better understanding of the sources of uncertainty when fitting multi-scale models to multi-scale infectious disease data, with a focus on Usutu and SARS-CoV-2 viruses. By combining empirical and theoretical approaches we aim to determine structural and practical parameter identifiability of multi-scale models, to inform optimal experimental design, and to improve our ability to make predictions and suggest interventions. Our proposal will focus on three major mathematical challenges: (1) Developing methods for improving practical identifiability in within-host systems; (2) Use experimental data to inform development of transmission models; (3) Build a quantitative framework to predict parameter identifiability in multi-scale systems. The overarching goal of the proposed work is to integrate multi-scale mathematical model development and statistical models for data fitting with collection of longitudinal virus titers and probability of transmission data in order to decrease uncertainty and improve results reproducibility. This will ultimately improve our understanding of infection disease transmission and persistence.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15329", "attributes": { "award_id": "1R01HL175642-01", "title": "The ADHINCRA Study: Addressing HypertensIoN Care in AfRicA", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31924, "first_name": "FERNANDO PEREIRA", "last_name": "Bruno", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-15", "end_date": "2029-06-30", "award_amount": 648073, "principal_investigator": { "id": 24505, "first_name": "Yvonne", "last_name": "Commodore-Mensah", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 31925, "first_name": "Dike Bevis", "last_name": "Ojji", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31926, "first_name": "Fred Stephen", "last_name": "Sarfo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Innovation in chronic disease management is urgently needed to effectively control hypertension (HTN) in Ghana and Nigeria. Both countries are suffering silent epidemics of chronic diseases with rates closely resembling those of high-income countries. Uncontrolled HTN causes cardiovascular disease, stroke, chronic kidney disease, and premature death. However, HTN is poorly controlled in both countries due to patient-, provider, and system-level barriers. A pressing global health challenge is implementing evidence-based and contextually appropriate strategies to improve chronic disease management in Ghana and Nigeria. Multilevel interventions improve HTN control. For instance, team-based care, a health systems-level and organizational intervention, improves the quality of HTN care. Telehealth can be enhanced with home blood pressure monitoring (HBPM) to address patient-, and provider-level barriers. The COVID-19 pandemic has spurred efforts to increase access to timely and appropriate care through re-engineering primary care to be patient- centered and digitally enabled. Sphygmo Home, a remote telemonitoring app that links with validated blood pressure (BP) and glucose monitoring devices, is a promising solution to improve patients’ self-management of chronic disease. In a previous pilot study, we investigated the impact of a multilevel and digitally-enabled home- based intervention compared to enhanced usual care (UC). After 12 months, 80.5% in the intervention arm, compared to 24.2% in the enhanced UC arm, had controlled BP (p <0.001). Given the promising findings, we designed a larger scale trial, consisting of an innovative multilevel intervention linking HBPM with a telemonitoring platform (Sphygmo Home app), team-based care including physicians and nurses, and the use of simplified hypertension treatment protocol at hospitals, to improve HTN control. Using a hybrid type 2 effectiveness-implementation design among 800 adults with uncontrolled HTN clustered in 16 hospitals across 3 regions (Ashanti, Northern, and Bono) in Ghana and in Ondo state, Nigeria, we seek to 1) Assess the effect of the ADHINCRA Program in improving BP control at 12 months using a stepped wedge cluster randomized trial of adults with uncontrolled HTN (systolic BP ≥140 mm Hg) and 2) Use the Pragmatic Robust Implementation and Sustainability Model (PRISM) to evaluate the reach, adoption, and maintenance of the ADHINCRA Program at 12- and 24-months post-randomization and explore contextual factors that are associated with the adoption and maintenance of the program in each site using the Service Availability and Readiness Assessment (SARA) tool. Through early and continued stakeholder engagement with health system leaders, providers, and patients, we seek to close the wide “know-do-gap” and reduce global chronic disease disparities. We also propose a comprehensive dissemination strategy to reach critical audiences and achieve buy-in, policy, and practice change.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15334", "attributes": { "award_id": "1K01AT012216-01A1", "title": "Harnessing implementation science to study stress management for correctional officers in jail settings", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Complementary and Integrative Health (NCCIH)" ], "program_reference_codes": [], "program_officials": [ { "id": 31931, "first_name": "JENNIFER NICOLE", "last_name": "Baumgartner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-17", "end_date": "2029-08-31", "award_amount": 132063, "principal_investigator": { "id": 31932, "first_name": "Margaret", "last_name": "Gorvine", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 772, "ror": "", "name": "UNIV OF ARKANSAS FOR MED SCIS", "address": "", "city": "", "state": "AR", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of this K01 Mentored Research Scientist Career Development award is to support Dr. Margaret Gorvine's current trajectory toward independent investigator status—via achieving the study aims and training goals to extend innovative research in the arenas of implementation science, integrative health, and criminal justice. Dr. Gorvine is an Instructor/ Postdoctoral Fellow in the Department of Health Behavior and Health Education in the College of Public Health, University of Arkansas for Medical Sciences (UAMS). Jail incarceration rates in the United States have tripled since the 1980s. More than 3,100 jails nationwide serviced 10.8 million jail admissions in 2018. Jail correctional officers (COs) are responsible for maintaining security and supervising detainees in facilities that are often low-resourced (e.g. funding, staffing shortages), are overcrowded, and replete with health risk exposures (e.g. Covid-19). Therefore, COs experience high levels of stress due to violence and low autonomy. The high risk of adverse mental health outcomes and health disparities among COs necessitates addressing CO stress management in jail settings. The study will use an evidence-based quality improvement (EBQI) method to achieve the first 2 aims including: 1) identifying barriers and facilitators to implementing a stress management intervention for correctional officers in a jail setting through formative evaluation (e.g. in-depth qualitative interviews with key jail stakeholders); 2) developing an implementation strategy package and intervention modifications. Thirdly, conduct a pilot hybrid type II effectiveness-implementation trial of the stress management intervention for correctional officers at the jail, measuring implementation outcomes of acceptability, appropriateness, feasibility, and fidelity of the intervention and the implementation strategy package. The training goals of the K01 Mentored Research Scientist Career Development award include: 1) developing expertise in implementation research methods related to intervention delivery in jails; 2) enhance skills in community-engaged research with partners within criminal justice settings; 3) learning how to build community-engaged partnerships in the jail; 4) developing expertise in evidence-based mind-body intervention delivery and research; and 5) Increase biostatistics expertise to be fully informed for in-depth collaboration with biostatisticians.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15351", "attributes": { "award_id": "1R21AG081823-01A1", "title": "Comprehensive Determination of Isoprostanoid Metabolism", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 31947, "first_name": "YI-PING", "last_name": "Fu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-23", "end_date": "2026-08-31", "award_amount": 478765, "principal_investigator": { "id": 31948, "first_name": "Ginger Lohr", "last_name": "Milne", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "Oxidative stress (OxS) is a biochemical process that leads to damage of cellular lipids when endogenous redox homeostasis is disrupted. OxS is mechanistically linked with the physiology of aging and age-related diseases, such as cardiovascular disease, neurodegeneration, cancer, frailty, diabetes, and SARS-CoV-2. The identification of biomarkers to measure OxS is thus of significant public health revelance in order to better understand disease mechanisms and target potential therapies. F2-Isoprostanes (F2-IsoPs) are formed from the oxidation of the cellular lipid arachidonic acid and considered to be excellent biomarkers of OxS. Currently, F2- IsoPs are being used as outcome measures in more than 80 active clinical trials worldwide. Further, the NIA- sponsored Interventions Testing Program (ITP) has identified nine agents that significantly increase lifespan, and four of those agents are known to decrease F2-IsoPs. While F2-IsoPs have proven to be useful biomarkers of OxS, our laboratory has obtained evidence to support the hypothesis that metabolites of F2- IsoPs more accurately reflect endogenous OxS than unmetabolized F2-IsoPs in certain biological settings. Yet, F2-IsoP metabolites are rarely quantified in clinical studies. F2-IsoP-like molecules (F-isoprostanoids) are made from the oxidation of other polyunsaturated fatty acids (PUFA), including adrenic, eicosapentaenoic (EPA), and docosahexaenoic acids. These compounds are proving to be useful biomarkers in neurodegenerative conditions and age-related macular degeneration, but their metabolism has never been studied. The central hypothesis of this proposal is that understanding the metabolism of F-isoprostanoids is critical for the accurate and complete quantitation of these urinary biomarkers in aging and OxS-related diseases. In Specific Aim 1, we will use human liver microsomes to identify metabolites of several F- isoprosatnoid isomers generated from the free radical oxidation of PUFA. Metabolites will be identified using mass spectrometry (MS). In Specific Aim 2, we will establish and validate a robust LC/MS method for the quantification of F-isoprostanoid metabolites, from Specific Aim 1, in human urine. For this purpose, we will utilize urine samples from The Fatty Acid Desaturase Activity, Fish Oil, and Colorectal Cancer Prevention Study (FnADAFO), a randomized clinical trial that was completed in 2018 at Vanderbilt. Subjects recruited in this study were supplemented with olive oil or marine fish oil for six months, so these urine samples are ideal for validation of this metabolite quantification. We anticipate that the completion of this application will redefine our understanding F2-IsoP metabolism and, for the first time, define a strategy to comprehensively assess this important biomarker of lipid peroxidation. Overall, these studies will change how the field evaluates endogenous OxS and lipid peroxidation, thus setting the stage for future applications examining the role of isoprostanoids in human physiology and the pathogenesis of disease.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15360", "attributes": { "award_id": "1UG3DA059278-01A1", "title": "Development of SBS-226, a MOR agonist / DOR antagonist, for OUD", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 31959, "first_name": "David A", "last_name": "White", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-30", "end_date": "2026-08-31", "award_amount": 3957359, "principal_investigator": { "id": 31960, "first_name": "Jeffrey", "last_name": "Reich", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2537, "ror": "", "name": "SPARIAN BIOSCIENCES, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Opioid use disorder (OUD) is a chronic disorder characterized by the repeated, compulsive use of opioid drugs with a detrimental impact to one’s physical, social, and psychological wellbeing. The use of prescription opiates is often necessary to control moderate to severe levels of pain. However, about 10% of patients prescribed an opiate for a medical condition are at risk for developing OUD. Opiate Use Disorder is a global problem but is at crisis levels in the U.S with significant mortality. It is estimated in this country that about ~11M misuse opioids, ~5.6M people have OUD and close to 80K died from opioid related overdoses. Sadly, the COVID epidemic has worsened the epidemic by increasing risk factors for OUD and occurred at a time when fentanyl has flooded the supply. Current treatments are primarily buprenorphine and methadone. Despite treatment options, OUD is difficult to effectively treat long-term due to access, stigma, and efficacy of the compounds. Mitragyna speciosa, a plant commonly known as kratom, has anecdotally been used for treatment of opiate withdrawal and OUD. The naturally occurring active substance is believed to be mitragynine and the 7- OH mitragynine (7OH) metabolite which act through the mu opioid receptor. An active metabolite of mitragynine, 7OH mitragynine, demonstrates MOR agonist properties such as analgesia, tolerance, physical dependence, and reinforcing effects. In contrast, an analog of mitragynine named 9-methoxy corynantheidine pseudoindoxyl (9CP) has a very different receptor binding profile and in vivo properties. 9CP is an partial agonist at MOR and it is also a delta opioid receptor (DOR) antagonist. Unlike the natural products found in kratom, when studied in mice under acute dosing 9CP is non-addictive, and demonstrates far less respiratory depression, tolerance, and signs of physical dependence than morphine. Most importantly, in mice, 9CP can ameliorate naloxone-precipitated withdrawal in morphine-dependent mice. Sparian has created a series of 9CP analogs and screened them across CMC, ADME, and PK properties and identified a lead candidate – SBS-226. Therefore, as an innovative pharmacological approach, we propose the development of SBS-226 as a novel selective, potent and non-addictive chemical entity utilizing mixed MOR agonism/DOR antagonism for the treatment of OUD. In the present application, we propose a full IND-enabling development plan and Phase 1 clinical trial.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15372", "attributes": { "award_id": "1R21NR021040-01A1", "title": "Barriers to Screen for Domestic Violence among Women in Emergency Department", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 31971, "first_name": "Dara", "last_name": "Blachman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-25", "end_date": "2026-08-31", "award_amount": 432542, "principal_investigator": { "id": 31972, "first_name": "Azade", "last_name": "Tabaie", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1515, "ror": "", "name": "MEDSTAR HEALTH RESEARCH INSTITUTE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Domestic violence (DV) includes physical and sexual violence, threats, economic, and emotional/psychological abuse, or other abusive behavior as part of a systematic pattern of control and power perpetrated by one intimate partner against another. It causes a significant burden for the healthcare systems by increasing morbidity and mortality among victims. Women are disproportionately affected, although men may experience DV as well. The recent COVID-19 pandemic led to movement restrictions and stay at home orders. While these decisions were essential to prevent spread of the virus, such extended domestic stays may exacerbate the number the total as well as reported incidents of DV. As a result, in recent years, DV has transformed into a shadow pandemic, which further complicated this public health issue and increased the need to perform accurate and timely interventions. DV often forms a pattern, and many of the victims experience repeated acts of physical or mental abuse. Victims of DV may seek care in hospital settings which makes timely interventions critical and even lifesaving. While there is a serious need for government to reinforce commitments made to eliminate all forms of DV against women, the health sector plays an essential role in breaking the cycle of abuse. Health providers can prevent reoccurrence of such violent incidents by identifying women who are experiencing DV, and then provide comprehensive services and train health providers in responding to the needs of survivors in addition to caring for physical injuries. Abused women rarely disclose the reason for emergency department (ED) visit due to various reasons including shame, fear of the perpetrator or financial dependencies. While these factors form patient-specific barriers to screen for DV, the barriers to screening, detecting and helping DV victims can be recognized at different levels during an ED visit. Since these barriers are not clear, more exploration is needed to understand important features by analyzing EHR data to gain further understanding of the clinical experience and environment. In Aim 1 of this proposal, we will use the DV-related ICD-9/ICD-10 diagnosis codes to find positive cases of DV among the visits to ED. Then adapt market-basket analysis, which is a data mining method originated in the field of marketing, to our objective and identify patterns of injury and health problems which are observed together frequently. Then, we will utilize state-of-the-art deep learning-based natural language processing (NLP) models to learn the patterns in electronic health records clinical notes related to DV. In Aim 2, we will conduct semi- structured interviews with ED health providers to investigate the barriers to screening for DV during patient- provider encounter. The outcomes of this study have the potential to add significant insights to improve the screening process and the care we provide our patients in the ED. 1", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15379", "attributes": { "award_id": "1R13FD008331-01", "title": "2024 FDA Retail Food Protection Seminar and Illinois Environmental Health Association’s Annual Education Conference", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 31980, "first_name": "Danielle", "last_name": "Head", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-30", "end_date": "2025-08-31", "award_amount": 50000, "principal_investigator": { "id": 31981, "first_name": "Anna Marie", "last_name": "Yates", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2538, "ror": "", "name": "ILLINOIS ENVIRONMENTAL HEALTH ASSOCIATION", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "FDA Support for Conferences and Scientific Meetings Funding Opportunity Announcement (FOA) Number: PAR-23-072 Participant: Illinois Environmental Health Association Program Dates: July 2024- December 2024 Project Summary Illinois Environmental Health Association is seeking funding from the FDA for the FDA Support for Conferences and Scientific Meetings Funding Opportnity. The funding will be used for the FDA/ IEHA Retail Food Seminar and Annual Education Conference in Chicago, Illinois. The Conference will be September 11-13, 2024 focusing on Food Safety. Our goal is to provide an opportunity for surrounding states to send their food program staff to a two and half day seminar where they will gain knowledge of food safety topics. Since the covid pandemic, it is pertinent that we continue providing opportunities for states to network and collaborate to keep up with the growing food integration. Our goal is to showcase the past, present, and future of public health through speakers and topics.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1405, "count": 14046 } } }